BlackRock Investment Management, LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 89 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Investment Management, LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q4 2016$4,610,000
-6.0%
144,619
+6.9%
0.01%
-16.7%
Q3 2016$4,902,000
+59.5%
135,265
-0.1%
0.01%
+50.0%
Q2 2016$3,073,000
+43.0%
135,449
+18.5%
0.00%
+33.3%
Q1 2016$2,149,000
+27.8%
114,300
+11.4%
0.00%
+50.0%
Q4 2015$1,681,000
+57.5%
102,583
+5.7%
0.00%
+100.0%
Q3 2015$1,067,000
-15.9%
97,093
-0.4%
0.00%
-50.0%
Q2 2015$1,269,000
+5.9%
97,491
+41.1%
0.00%0.0%
Q1 2015$1,198,000
+17.2%
69,071
+0.9%
0.00%
+100.0%
Q4 2014$1,022,000
-35.8%
68,488
-0.8%
0.00%
-50.0%
Q3 2014$1,591,000
-27.4%
69,013
+0.4%
0.00%
-33.3%
Q2 2014$2,190,00068,7070.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2015
NameSharesValueWeighting ↓
Chescapmanager LLC 1,157,718$17,117,0002.77%
Baupost Group 8,735,168$129,149,0001.40%
Orbimed Advisors 6,219,110$91,950,0001.16%
Rubric Capital Management LP 550,747$8,143,0000.76%
Cormorant Asset Management, LP 650,072$9,611,0000.37%
Rock Springs Capital Management LP 824,018$12,183,0000.31%
Virtus ETF Advisers LLC 23,148$342,0000.18%
Tekla Capital Management LLC 298,470$4,413,0000.16%
PEREGRINE CAPITAL MANAGEMENT LLC 412,594$6,100,0000.16%
NJ State Employees Deferred Compensation Plan 38,142$564,0000.10%
View complete list of THERAVANCE BIOPHARMA INC shareholders